Finpecia

Legal status and availability in the UK

In our online pharmacy, Finpecia is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Finpecia information

• INN (international nonproprietary name): Finasteride
• Brand names available in the United Kingdom: Propecia (1 mg) and Proscar (5 mg), plus generic finasteride tablets.
• ATC code: D11AX10 (androgenetic alopecia); G04CB01 (benign prostatic hyperplasia)
• Forms and dosages: 1 mg tablet for male pattern hair loss; 5 mg tablet for benign prostatic hyperplasia (BPH)
• Manufacturers: Merck & Co. (MSD), Teva and other generic manufacturers; Finpecia is made by Cipla
• Registration status in the United Kingdom: MHRA licensed for Propecia 1 mg, Proscar 5 mg and generic finasteride; prescription only
• OTC / Rx classification: prescription only (Rx)

Clinical effectiveness in the UK

How well does finasteride work?

Finasteride 1 mg produces measurable hair stabilisation and regrowth in most men who take it consistently, after about three to six months.

Visible, peak benefit is commonly reported by around twelve months, and the effect requires ongoing daily therapy to be maintained.

For BPH, Proscar 5 mg reduces prostate volume and improves urinary symptoms after six months or more, and is frequently prescribed alongside alpha‑blockers for symptomatic control.

Common challenges are expectation management, adherence drop‑off when benefits are delayed, and concern about sexual side effects.

Indications and expanded uses (MHRA‑approved vs off‑label)

What is finasteride licensed for, and when is off‑label use considered?

• MHRA‑approved indications: Finasteride 1 mg (Propecia/generics) — male androgenetic alopecia; Finasteride 5 mg (Proscar/generics) — benign prostatic hyperplasia. Both are prescription‑only.
• Not approved: Not licensed for women or children; pregnancy exposure is an absolute contraindication because of risk to a male foetus.
• Off‑label use: any off‑label use (for example, low‑dose combination regimens) is limited in UK practice and should be specialist‑supervised.

MHRA

UK Medicines and Healthcare products Regulatory Agency, responsible for licensing in the UK.

Rx‑only

Prescription only; supply requires an authorised prescription.

Composition and brand landscape

What is inside the tablet and which brands are commonly seen in the UK?

The active ingredient is finasteride (INN), with ATC codes D11AX10 for alopecia and G04CB01 for BPH.

Original brands include Propecia 1 mg and Proscar 5 mg from Merck & Co.

Generic finasteride is made by several manufacturers; Finpecia (1 mg) is a finasteride generic made by Cipla.

Pharmacists should check manufacturer branding, batch numbers and packaging when dispensing finasteride tablets.

Contraindications and special precautions

Who should not use finasteride, and what handling cautions are essential?

Absolute contraindications

Pregnancy — finasteride is a known teratogen and may cause male foetal external genital abnormalities.

Women and children — not indicated or safe.

Known hypersensitivity to finasteride or excipients.

Relative precautions

Significant hepatic impairment — use with caution as finasteride is metabolised hepatically.

Severe lower urinary tract obstruction — monitor closely if BPH is advanced.

Handling warning: Do not split or crush tablets, and advise pregnant contacts to avoid handling broken tablets.

There are no routine driving or activity restrictions, but counsel patients about mood changes and sexual dysfunction which could affect daily activities.

Dosage guidelines

What doses are recommended on the NHS and how should patients take finasteride?

If a dose is missed, take it as soon as remembered that day, but do not double the next dose.

In overdose, there is no specific antidote and management is supportive; large amounts are not expected to be life threatening.

Elderly patients usually do not need dose reduction, but monitor for adverse events and use caution in hepatic impairment.

Interactions overview

Which drugs and lifestyle factors interact with finasteride, and what have regulators recorded?

Finasteride has few pharmacokinetic interactions because it is not a major CYP substrate.

Common co‑prescriptions in BPH include alpha‑blockers such as tamsulosin; monitor blood pressure and symptom response when combining therapies.

MHRA Yellow Card reports have recorded psychiatric events (depression, mood changes) and sexual dysfunction, though causality is mixed in the literature.

There are no clinically significant food interactions; alcohol does not alter finasteride pharmacology but may worsen mood or sexual side effects in some patients.

• Monitor when co‑prescribing with alpha‑blockers for orthostatic symptoms.
• Report suspected adverse reactions via Yellow Card to support safety surveillance.

Comparable medicines and preferences

What are the main alternatives to finasteride for hair loss and BPH?

Dutasteride (Avodart) inhibits both type I and II 5α‑reductase and often lowers DHT more than finasteride, with some evidence of greater efficacy in hair‑loss measures.

Topical minoxidil is a standard non‑systemic option and is frequently used in combination with oral finasteride for additive benefit.

Herbal supplements such as saw palmetto or pumpkin seed oil have variable evidence and are not MHRA‑approved for hair loss or BPH.

Clinicians should weigh potential efficacy gains against side‑effect risk and patient preference when discussing alternatives.

FAQ: common NHS patient questions

What do patients typically ask at the pharmacy or GP about finasteride?

Q: How long until I see results?

A: Expect first changes by about three months and clearer regrowth by six to twelve months; continued daily use is required to maintain benefits.

Q: Will finasteride affect my sex life?

A: Some men experience reduced libido, erectile dysfunction or ejaculatory changes; most of these side effects resolve after stopping, but a small subset report persistent symptoms.

Q: Can women or pregnant partners be exposed?

A: Women of childbearing potential and pregnant women must not handle crushed tablets; finasteride is contraindicated in women, and exposure during pregnancy is a serious risk.

Q: Do I need blood tests or monitoring?

A: Routine blood tests are not usually required for hair‑loss prescribing; for BPH a baseline assessment and urology follow‑up are common practice.

• When to contact the GP: new or worsening mood changes, sexual dysfunction, breast changes or signs of allergic reaction.

Guidelines for proper use

What should pharmacists tell patients when dispensing finasteride?

• Confirm indication and patient age, and ensure women of childbearing potential are counselled about handling risks.
• Explain the dose: finasteride 1 mg once daily for alopecia; 5 mg once daily for BPH.
• Set expectations: timeline of 3–12 months for hair results and ≥6 months for BPH; continuous use required to maintain effects.
• Advise on sexual and mood side‑effect monitoring, and encourage Yellow Card reporting for suspected adverse reactions.
• Storage: keep in original packaging, below 30°C, away from moisture and light; do not split or crush tablets.

Patients should know the dose and timing, missed‑dose advice, the expected timeline, the main side effects to watch for, and when to contact their GP or NHS 111.

Delivery across the United Kingdom